a

Debiopharm leads YonaLink’s $6 million round to expand global growth and fuel expansion of platform designed to stream clinical trial data

Debiopharm leads YonaLink’s $6 million round to expand global growth and fuel expansion of platform designed to stream clinical trial data

SaaS platform provides a missing link in clinical trial data collection, automating the secure transfer of real-time patient data from electronic health records to EDC systems

Technology brings new levels of speed, quality and effectiveness to clinical trial data collection and validation across the globe and treatment areas

Boston and Lausanne, SwitzerlandAnd the November 9, 2022 /PRNewswire/- Debiopharm Innovation Fund, The strategic investment arm of the Swiss biopharmaceutical company DebiopharmAnd the YonaLink, a clinical trial software provider, today announced the completion of an initial funding round, an increase in the number of 6 million dollars, to scale global growth and expand the YonaLink EHR-to-EDC integration platform. Designed for the purpose of broadcasting and mapping updated patient data, YonaLink’s SaaS solution, in real time, exports patient data directly from the clinical site’s electronic health record system and transmits it to Clinical Research Electronic Data Capture (EDC) systems.

Debiopharm Innovation Fund in Switzerland led the tour. Co-financed by the European Union, the tour also included Israel eHealth projects. the total 6 dollars The 1 million investment will be used to bring more talent to the company’s growing team, expand the capabilities of the YonaLink platform, and boost its adoption among clinical trial sponsors and their Clinical Research Organization (CRO) partners.

“YonaLink bridges the gap between patient care and clinical research, providing the missing link in clinical trial data collection and validation with technology that securely delivers true EHR to EDC connectivity, without disrupting existing clinical trial workflows,” Edo Belig, CEO and co-founder of YonaLink. “We are excited to bring our technology to more clinical trials – starting with the US, EuropeAnd the Israel To help drive innovation in clinical development and accelerate the delivery of important new treatments to patients across disease states and therapeutic areas.”

The YonaLink platform has the capabilities to stream up-to-date data from any EHR system to any clinical site, in any part of the world, and deploy it to next-generation YonaLink or other data capture systems. With integrated eConsent and ePRO/eCOA and streaming EHR-to-EDC capabilities, the next generation of YonaLink EDC provides a comprehensive solution to today’s clinical trial needs, bringing EDC and eSource functionality together in one tool.

“Real-world data from electronic health records has long been an untapped resource for clinical trials, which can enhance the efficiency of clinical trials, improve patient outcomes and, ultimately, make research data collection a by-product of routine clinical record keeping,” he said. Vincent Lebro, Associate Director of the Debiopharm Innovation Fund. “We invested in YonaLink because we believed that the way clinical trials were conducted in the past had to be fundamentally disrupted. YonaLink’s data-flow technology trains for one of the obvious shortcomings of drug development — moving data from electronic health records to EDCs. No one should You do it manually anymore.”

Ophir ShehafMD, partner at eHealth Ventures, added: “While clinical trial data capture and management has evolved from paper to software, it is still labor intensive and largely manual processes. YonaLink is changing the paradigm with a solution that provides true automation. This technology can be used to help reduce The burden on research sites, lower trial costs, and enabling efficiencies that speed up time to market for clinical trial sponsors. This in turn makes a meaningful difference for patients waiting for new treatments, which is why we are thrilled to be a part of YonaLink’s journey and this latest funding round.”

About YonaLink

YonaLink provides research teams with the ability to extract up-to-date patient data from electronic health records and stream that data into a real-time Electronic Data Capture for Clinical Trials (EDC) system, reducing clinical trial timelines and costs. Headquartered in Boston With research and development operations in IsraelYonaLink brings new levels of speed, quality, and efficiency to clinical trial operations worldwide, simplifying the complexity of clinical data collection and validation, and enabling true scalability. The company’s SaaS platform has the capabilities to stream updated data from any EHR platform to any clinical site, in any part of the world, and deploy it to next-generation YonaLink or other data capture systems. With built-in eConsent, ePRO/eCOA, and streaming EHR-to-EDC capabilities, the next generation of YonaLink EDC provides a comprehensive solution to today’s clinical trial needs, bringing EDC and eSource functionality together in one tool that can be set up in minutes, eliminating integration delays, and reducing costs, and speed up study schedules. Learn more at www.yonalink.com.

About the Debiopharm Innovation Fund

The Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides strategic funding and guidance to companies aspiring to improve the patient journey, and reimagine how clinical trials are conducted, along with companies offering digital platforms that support the latest technology. drug techniques. Since 2017, Debiopharm has invested in 14 digital health companies, usually leading the investment rounds.

About eHealth Ventures (eHV)

The eHealth Ventures Partnership is a leading investor in early-stage digital health companies. It includes two venture capital funds, a technology incubator focused exclusively on digital health, and significant undiluted government funding. Partners include Maccabi (a leading Israeli healthcare fund), Amgen (global biotech giant), Mayo Clinic, Madison Ventures, Arad Investments, and Hadar Group. The team has reviewed over 1,600 companies to date and invested in a portfolio of 24 highly innovative companies (digital diagnostics, therapeutics, home care, and bio-convergence). Their focus is on finding, financing, and growing promising early-stage digital health companies. They work closely with star entrepreneurs, true innovators, and game-changers in this exciting industry.

Contacts

SOURCE Debiopharm International SA


#Debiopharm #leads #YonaLinks #million #expand #global #growth #fuel #expansion #platform #designed #stream #clinical #trial #data

Leave a Comment

Your email address will not be published. Required fields are marked *